What does the burden of gMG really mean for patients?

gMG impacts patients’ physical and psychological well-being1,2

Patients with generalized myasthenia gravis (gMG) often struggle with activities of daily living because of incomplete symptom control.1

The management of gMG may vary considerably10,11

Because gMG is heterogeneous, it requires individualized treatment approaches. While many patients respond well to commonly used treatments, it may take months to see results, and there are some patients who do not find any symptomatic relief.6,12,13

Existing health conditions may have implications for the management of gMG in some patients. In an observational cohort study designed to determine the impact of comorbidities in patients with gMG, 73% of the 253 patients had comorbidities, such as dyslipidemia, diabetes, and hypertension, which may have contributed to a worsening of their gMG prognosis.14

Find out what the burden of gMG really means and why there is more work to be done. 

References: 1. Twork S et al. Health Qual Life Outcomes. 2010;8:129. doi:10.1186/1477-7525-8-129 2. Boldingh MI et al. Health Qual Life Outcomes. 2015;13:115. doi:10.1186/s12955-015-0298-1 3. Howard JF. Myasthenia Gravis: A Manual for the Health Care Provider. Myasthenia Gravis Foundation of America; 2009. 4. Suzuki Y et al. BMJ Open. 2011;1(2):e000313. doi:10.1136/bmjopen-2011-000313 5. Liu D et al. Allergy Asthma Clin Immunol. 2013;9(1):30. doi:10.1186/1710-1492-9-30 6. Gotterer L, Li Y. J Neurol Sci. 2016;369:294-302. doi:10.1016/j.jns.2016.08.057 7. Guo Y et al. Front Immunol. 2018;9:1299. doi:10.3389/fimmu.2018.01299 8. Grob D et al. Muscle Nerve. 2008;37(2):141-149. doi:10.1002/mus.20950 9. Wendell LC, Levine JM. Myasthenic crisis. Neurohospitalist. 2011;1(1):16-22. doi:10.1177/1941875210382918 10. Sieb JP. Clin Exp Immunol. 2014;175(3):408-418. doi:10.1111/cei.12217 11. Sussman J et al. Ann N Y Acad Sci. 2018;1412(1):166-169. doi:10.1111/nyas.13503 12. Sanders DB et al. Neurology. 2016;87(4):419-425. doi:10.1212/WNL.0000000000002790 13. Gilhus NE et al. Nat Rev Dis Primers. 2019;5(1):30. doi:10.1038/s41572-019-0079-y 14. Cacho Diaz B et al. J Neurol Neurophysiology. 2015;6:5. doi: 10.4172/2155-9562.1000317